Wortmannin

SKU: orb1300904

Description

Wortmannin

Research Area

Product Categories/Products/Small Molecules,Autophagy|||DNA Damage/DNA Repair|||Metabolism|||Cell Cycle/Checkpoint|||Microbiology/Virology|||PI3K/Akt/mTOR signaling

Key Properties

• CAS Number: 19545-26-7
• MW: 428.43
• Purity: 99.76%
• Formula: C₂₃H₂₄O₈
• SMILES: COCC1OC(=O)c2coc3c2C1(C)C1=C(C2CCC(=O)C2(C)CC1OC(C)=O)C3=O

Bioactivity

• Target IC50:
  DNA-PK:16 nM|MLCK:200 nM|PI3K:3 nM|ATR:1.8 μM|PLK3:48 nM|ATM:150 nM
• In Vivo:
  METHODS: To determine whether activation of the insulin pathway and brain enlargement were responsible for fatal seizures, Wortmannin (1.5 mg/kg) was administered orally to Pcmt1-/- mice once a day for twenty-two days. RESULTS: Wortmannin reduced the average brain size of Pcmt1-/- mice to within 6% of that of controls and nearly doubled the lifespan of Pcmt1-/- mice, with a survival rate of 60% of the original population. METHODS: To investigate antitumor activity, Wortmannin (0.25-1 mg/kg) was injected intravenously three times a week for three weeks into SCID mice bearing the human breast cancer tumor MDA-MB-231. RESULTS: Wortmannin significantly inhibited tumor metastasis and angiogenesis.
  Read more...
• In Vitro:
  METHODS: Human breast cancer cells MCF-7 were treated with Wortmannin (50-500 nM) for 24 h. Cell death was detected by Trypan blue exclusion assay. RESULTS: Wortmannin induced cell death in MCF-7 cells in a concentration-dependent manner with an IC50 of 400 nM. METHODS: Human breast cancer cells MCF-7 were treated with Wortmannin (6.25-50 nM) for 24 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Concentration-dependent reduction of p-Akt and NF-κB p65 expression was induced by Wortmannin.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

5691